INX-315 is an oral, investigational selective cyclin-dependent kinase 2 (CDK2) inhibitor. The designation was based on preclinical data as well as interim data from the ongoing phase 1/2 INX-315-01 ...

STAAR Low-Grade Serous Ovarian Cancer Foundation and Not These Ovaries Fund Breakthrough Research at MD Anderson Cancer ...

Ovarian cancer is a cancer in the ovary that is located on both sides of the uterus to produce follicles and make female ...

One ovary contained a rare serous cystadenofibroma, while the other had a collision tumor—two distinct cyst types, serous and mucinous, growing side by side without mixing. This specific tumor ...

INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian ...

For a long time, scientists thought this cancer came from the ovaries. But this new research, led by Professor Alexander ...

Fast Track designation highlights potential of INX-315 to address unmet need for patients with recurrent advanced/metastatic ...

One ovary contained a rare serous cystadenofibroma, while the other had a collision tumor-two distinct cyst types, serous and mucinous, growing side by side without mixing. This specific tumor ...

Pharmacogenomics. 2012;13(13):1523-1535. 5-year survival for stage III and IV (%): carriers, 38.1; noncarriers, 24.5 Median survival: p = 0.002 5-year survival for stage III and IV: p < 0.001 [46 ...

Women with ovarian mesothelioma should have never been included in the Talc Powder MD, as there is no cause of this diagnosis ...

Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at ...